I remain cautiously optimistic about Agenus, driven by BOT/BAL's strong clinical data and cost-reduction efforts, but maintain a speculative 2/5 conviction rating. The BOT/BAL program shows promising efficacy in MSS colorectal cancer, potentially resetting the standard of care and offering a significant commercial opportunity. Agenus's restructuring, asset monetization, and cost cuts aim to ext...
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus” or the Company”) (NASDAQ: AGEN), a leader in immuno-oncology, today announced new data from its ongoing Phase 1 trial evaluating botensilimab and balstilimab (BOT/BAL) in patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC) at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress ...
Agenus Inc. (NASDAQ:AGEN ) Q1 2025 Earnings Conference Call May 12, 2025 8:30 AM ET Company Participants Zack Armen - Head of Investor Relations Garo Armen - Chairman and CEO Steven O'Day - Chief Medical Officer Robin Taylor - Chief Commercial Officer Richard Goldberg - Chief Development Officer Christine Klaskin - VP Finance and Principal Financial and Accounting Officer Conference Call Partic...
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus” or the “Company”) (NASDAQ: AGEN), a leader in immuno-oncology, today reported financial and operational results for the first quarter of 2025, and shared key clinical and strategic milestones supporting the advancement of its botensilimab (BOT) and balstilimab (BAL) program. “The growing strength of our BOT/BAL data across multiple hard-t...
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation today announced that Dr. Richard M. Goldberg, an internationally recognized expert in gastrointestinal (GI) cancer treatment and research, has joined the company as Chief Development Officer. In this role, Dr. Goldberg will lead efforts to advance the botensilimab/balstilimab (BOT/BAL) program ...
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its first quarter 2025 financial results before the market opens on Monday, May 12th. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provid...
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that data from the investigator sponsored NEOASIS study were presented in an oral session at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, Illinois. This represents the third clinical study evaluating botensilimab and balstilimab (BOT/BAL) in the neoadjuva...
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a clinical-stage immuno-oncology company, today announced updated data from the hepatocellular carcinoma (HCC) cohort of its ongoing Phase 1 study evaluating botensilimab (BOT) in combination with balstilimab (BAL). These findings are being presented at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, I...
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.